Atricure reports first quarter 2024 financial results

Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in surgical treatments and therapies for atrial fibrillation (afib), left atrial appendage (laa) management and post-operative pain management, today announced first quarter 2024 financial results. “we are proud to announce a strong start to 2024, marked by growth across each of our franchises worldwide,” said michael carrel, president and chief executive officer at atricure. “we remain diligently focused on expand.
ATRC Ratings Summary
ATRC Quant Ranking